{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:37:33Z","timestamp":1792741053941,"version":"4.5.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1097\/fjc.0b013e3180325b0a","type":"journal-article","created":{"date-parts":[[2007,4,10]],"date-time":"2007-04-10T04:02:42Z","timestamp":1176177762000},"page":"228-235","source":"Crossref","is-referenced-by-count":70,"title":["Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression"],"prefix":"10.1097","volume":"49","author":[{"given":"Yung-Wu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morey L","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Ballaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Trevillyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Bauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennan","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Fey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Gauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl W","family":"Mollison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan W","family":"Djuric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210208","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.","volume":"28","author":"Vezina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"R2-7-20210208","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7164\/antibiotics.28.727","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.","volume":"28","author":"Sehgal","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"R3-7-20210208","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0277-5379(83)90012-3","article-title":"Human brain tumor xenografts as a chemotherapy model.","volume":"19","author":"Houchens","year":"1983","journal-title":"Eur J Clin Oncol"},{"key":"R4-7-20210208","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.7164\/antibiotics.37.1231","article-title":"Activity of rapamycin (AY-22,989) against transplanted tumors.","volume":"37","author":"Eng","year":"1984","journal-title":"J Antibiot (Tokyo)"},{"key":"R5-7-20210208","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1139\/y77-007","article-title":"Inhibition of the immune response by rapamycin, a new antifungal antibiotic.","volume":"55","author":"Martel","year":"1977","journal-title":"Can J Physiol Pharmacol"},{"key":"R6-7-20210208","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(89)90417-0","article-title":"Rapamycin for immunosuppression in organ allografting.","volume":"2","author":"Calne","year":"1989","journal-title":"Lancet"},{"key":"R7-7-20210208","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.","volume":"349","author":"Moses","year":"2003","journal-title":"N Engl J Med"},{"key":"R8-7-20210208","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"R9-7-20210208","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.","volume":"270","author":"Sabers","year":"1995","journal-title":"J Biol Chem"},{"key":"R10-7-20210208","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"R11-7-20210208","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506.","volume":"80","author":"Ho","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"R12-7-20210208","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/00007890-199805150-00023","article-title":"Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin).","volume":"65","author":"Brattstrom","year":"1998","journal-title":"Transplantation"},{"key":"R13-7-20210208","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0041-1345(03)00213-6","article-title":"Bicentre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study.","volume":"35","author":"Charpentier","year":"2003","journal-title":"Transplant Proc"},{"key":"R14-7-20210208","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/01.TP.0000074310.40484.94","article-title":"Dislipidemia in renal transplant recipients treated with a sirolimus and cyclosporin-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.","volume":"76","author":"Chueh","year":"2003","journal-title":"Transplantation"},{"key":"R15-7-20210208","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.TP.0000128628.31556.B1","article-title":"A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-related complications.","volume":"78","author":"Montalbano","year":"2004","journal-title":"Transplantation"},{"key":"R16-7-20210208","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","article-title":"Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management.","volume":"69","author":"Hong","year":"2000","journal-title":"Transplantation"},{"issue":"Suppl B","key":"R17-7-20210208","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1016\/S0149-2918(00)89027-X","article-title":"Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.","volume":"22","author":"MacDonald","year":"2000","journal-title":"Clin Ther"},{"key":"R18-7-20210208","first-page":"573","article-title":"Clinical pharmacokinetics of sirolimus.","volume":"40","author":"Mahalati","year":"2001","journal-title":"Drug Disp"},{"key":"R19-7-20210208","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007691-200010000-00006","article-title":"Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers.","volume":"2","author":"Brattstrom","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R20-7-20210208","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/jmbi.1993.1012","article-title":"Atomic structure of the human immunophilin FKBP-12 complexes with FK506 and rapamycin.","volume":"229","author":"Van Duyne","year":"1993","journal-title":"J Mol Biol"},{"key":"R21-7-20210208","first-page":"736","article-title":"Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution.","volume":"D55","author":"Liang","year":"1999","journal-title":"Acta Cryst"},{"key":"R23-7-20210208","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1016\/j.bmcl.2005.06.106","article-title":"Rapamycin analogs with reduced systemic exposure.","volume":"15","author":"Wagner","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"R24-7-20210208","first-page":"644","article-title":"Evaluation of calcineurins role in the immunosuppressive activity of FK506, related macrolactams, and cyclosporine.","volume":"25","author":"Lane","year":"1993","journal-title":"Transplant Proc"},{"key":"R25-7-20210208","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1056-8719(97)00106-8","article-title":"Improved methods for transplanting split-heart neonatal cardiac grafts into the ear pinna of mice and rats.","volume":"39","author":"Fey","year":"1998","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R26-7-20210208","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/138161280405221010155826","article-title":"Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.","volume":"4","author":"Mollison","year":"1998","journal-title":"Curr Pharmaceutical Design"},{"key":"R27-7-20210208","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1006\/clin.1993.1138","article-title":"Divergent effects of rapamycin on mouse and rat following mitogenic stimulation.","volume":"68","author":"Olivera","year":"1993","journal-title":"Clin Immunol Immunopathol"},{"key":"R28-7-20210208","first-page":"1125","article-title":"Rapamycin, a potential disease-modifying antiarthritic drug.","volume":"266","author":"Carlson","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R29-7-20210208","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1139\/y77-007","article-title":"Inhibition of the immune response by rapamycin, a new antifungal antibiotic.","volume":"55","author":"Martel","year":"1977","journal-title":"Can J Physiol Pharmacol"},{"key":"R30-7-20210208","first-page":"326","article-title":"Anti-restenosis trials.","volume":"2","author":"de Feyter","year":"2000","journal-title":"Curr Interv Cardiol Rep"},{"key":"R31-7-20210208","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0735-1097(02)01989-7","article-title":"In-stent restenosis in small coronary arteries: impact of thickness.","volume":"40","author":"Briguori","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R32-7-20210208","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1067\/mhj.2001.118744","article-title":"Randomized comparison of J J Crown stent versus NIR stent after routine coronary angioplasty.","volume":"142","author":"Miketic","year":"2001","journal-title":"Am Heart J"},{"key":"R33-7-20210208","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00007890-199502150-00014","article-title":"Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth and platelet-derived growth factor action and antagonism of sirolimus by FK506.","volume":"59","author":"Cao","year":"1995","journal-title":"Transplantation"},{"key":"R34-7-20210208","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/hc4201.098056","article-title":"Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up.","volume":"104","author":"Sousa","year":"2001","journal-title":"Circulation"},{"key":"R35-7-20210208","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1053\/euhj.2001.2892","article-title":"Coronary restenosis elimination with sirolimus eluting stent. First European human experience with 6-month angiographic and intravascular ultrasonic follow-up.","volume":"22","author":"Rensing","year":"2001","journal-title":"Eur Heart J"},{"key":"R36-7-20210208","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ccd.20348","article-title":"Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model.","volume":"65","author":"Collingwood","year":"2005","journal-title":"Catheter Cardiovasc Interv"},{"key":"R37-7-20210208","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/eurheartj\/ehi752","article-title":"Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks.","volume":"27","author":"Garcia-Touchard","year":"2006","journal-title":"Eur Heart J"},{"key":"R38-7-20210208","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.addr.2006.01.021","article-title":"Zotarolimus (ABT-578) eluting stents.","volume":"58","author":"Burke","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"R39-7-20210208","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF03190588","article-title":"Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1\/2 be predicted from in-vivo rat data?","volume":"29","author":"Caldwell","year":"2004","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R40-7-20210208","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00044011-200525080-00001","article-title":"Pharmacokinetics and safety of ABT-578, a sirolimus (rapamycin) analogue, after single intravenous bolus injection in healthy male volunteers.","volume":"25","author":"Palaparthy","year":"2005","journal-title":"Clin Drug Invest"},{"key":"R41-7-20210208","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/0091270005278807","article-title":"A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects.","volume":"45","author":"Karyekar","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R42-7-20210208","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1177\/00912700022009017","article-title":"Prospective allometric scaling: does the emperor have clothes?","volume":"40","author":"Bonate","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"R43-7-20210208","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1211\/0022357991773320","article-title":"Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study.","volume":"51","author":"Mahmood","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"R44-7-20210208","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.105.591206","article-title":"Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial.","volume":"114","author":"Fajadet","year":"2006","journal-title":"Circulation"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00005344-200704000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T07:40:42Z","timestamp":1683790842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-200704000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0b013e3180325b0a","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}